The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The evolution of BCL2 inhibition in CLL
John Seymour, MBBS, FRACP, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the history and evolution of BCL2 inhibition in chronic lymphocytic leukemia (CLL). He highlights the progression from early, less effective agents to potent BCL2 inhibitors that have become foundational in time-limited combination treatments for achieving high rates of measurable residual disease (MRD) negativity. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
